- Home
- IMAB vs AVTX Comparison
IMAB vs AVTX Comparison
Compare IMAB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- AVTX
- Stock Information
- Founded
- IMAB 2014
- AVTX 2011
- Country
- IMAB United States
- AVTX United States
- Employees
- IMAB N/A
- AVTX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- AVTX Health Care
- Exchange
- IMAB Nasdaq
- AVTX Nasdaq
- Market Cap
- IMAB 384.6M
- AVTX 138.8M
- IPO Year
- IMAB 2020
- AVTX 2015
- Fundamental
- Price
- IMAB $3.69
- AVTX $11.33
- Analyst Decision
- IMAB Strong Buy
- AVTX Strong Buy
- Analyst Count
- IMAB 5
- AVTX 9
- Target Price
- IMAB $6.80
- AVTX $30.14
- AVG Volume (30 Days)
- IMAB 1.7M
- AVTX 188.1K
- Earning Date
- IMAB 11-02-2025
- AVTX 11-06-2025
- Dividend Yield
- IMAB N/A
- AVTX N/A
- EPS Growth
- IMAB N/A
- AVTX N/A
- EPS
- IMAB N/A
- AVTX N/A
- Revenue
- IMAB N/A
- AVTX $441,000.00
- Revenue This Year
- IMAB N/A
- AVTX N/A
- Revenue Next Year
- IMAB N/A
- AVTX N/A
- P/E Ratio
- IMAB N/A
- AVTX N/A
- Revenue Growth
- IMAB N/A
- AVTX N/A
- 52 Week Low
- IMAB $0.60
- AVTX $3.39
- 52 Week High
- IMAB $5.90
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- IMAB 45.33
- AVTX 62.61
- Support Level
- IMAB $3.20
- AVTX $9.54
- Resistance Level
- IMAB $4.64
- AVTX $12.41
- Average True Range (ATR)
- IMAB 0.41
- AVTX 1.05
- MACD
- IMAB -0.17
- AVTX -0.10
- Stochastic Oscillator
- IMAB 29.88
- AVTX 71.28
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).